---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-112123"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:54:34.781125+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics files prospectus supplement for up to $3.4M ATM offering

## Summary
- Filed prospectus supplement to sell up to $3,438,062 of common stock via ATM program with H.C. Wainwright.
- As of Nov 18, 2025, $9,386,964 of common stock already sold under the same ATM agreement dated March 11, 2024.
- Wainwright will receive 3.0% commission on gross sales; Company has no obligation to sell shares.
- Legal opinion from Blank Rome LLP attached as Exhibit 5.1.

## SEC filing metadata
- accession: 0001213900-25-112123
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025112123/0001213900-25-112123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025112123/ea0266097-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-112123
- JSON: https://secwatch.observer/filing/0001213900-25-112123.json
- Plain text: https://secwatch.observer/filing/0001213900-25-112123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.